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Abstract: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder affecting upper
and lower motor neurons (MNs) that still lacks an efficacious therapy. The failure of recent therapeutic
trials in ALS, other than depending on the poor knowledge of pathogenic mechanisms responsible
for MNs loss, is largely due to diagnostic delay and the lack of reliable biomarkers for diagnosis,
prognosis and response to pharmacologic intervention. Neurofilaments (Nfs) are neuron-specific
cytoskeletal proteins, whose levels increased in biological fluids proportionally to the degree of
axonal damage, both in normal and in pathologic conditions, representing potential biomarkers
in various neurological disorders, such as motor neuron disorder (MND). Growing evidence has
shown that phosphorylated neurofilaments heavy chain (p-NfH) and neurofilaments light chain
(NfL) are increased in blood and cerebrospinal fluid (CSF) of ALS patients compared to healthy and
neurological controls and are found to correlate with disease progression. In this review, we reported
the most relevant studies investigating the diagnostic and prognostic role of Nfs in ALS. Given their
reliability and reproducibility, we consider Nfs as promising and useful biomarkers in diagnosis of
MND, early patient identification for inclusion in clinical trials, prediction of disease progression,
and response to pharmacological intervention, and we suggest the validation of their measurement
in clinical activity.
Keywords: amyotrophic lateral sclerosis; neurofilaments; p-NfH; NfL; cerebrospinal fluid;
blood; biomarkers
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder affecting upper and lower
motor neurons (MNs) that still lacks an efficacious therapy. In the past decades, several studies have
been led to find a molecule able to halt disease progression, but they were unsuccessful. The incomplete
knowledge of pathophysiological mechanisms underlying ALS and the lack of available and reliable
biomarkers for diagnosis, disease progression, prognosis, and response to pharmacologic intervention
has limited the clinical experience about motor neuron disorders (MND) and has probably contributed
to the failure of recent therapeutic trials in ALS.
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An ideal biomarker would have higher levels of expression in patients compared with controls,
would maintain steady levels throughout the disease course, being susceptible to treatment effects and
disease exacerbations, and would reflect the rate of neurological decline and the disease duration.
Evidence showing that neurofilaments (Nfs) are found at elevated concentrations in cerebrospinal
fluid (CSF) and blood of patients affected by ALS, has prompted the scientific research to explore their
role as diagnostic and prognostic biomarkers in ALS.
Nfs are neuron-specific cytoskeletal proteins with a characteristic diameter of 8–10 nm, and are
members of the intermediate filament family (Figure 1A) [1]. They are present in cell bodies and
axons and are involved in growth, stabilization and polarization of neural cells, enabling effective
axonal conduction. According to the molecular mass of their subunits, Nfs are classified in light (NfL),
medium (NfM) and heavy chain (NfH). Nfs subunits are formed by a conserved α-helical rod domain,
a variable amino-terminal globular head region and a carboxy-terminal tail domain [2]. Assembly
of neurofilament protein monomers in heterodimers, and then in tetramers, is followed by lateral
association of eight tetramers, resulting in the formation of cylindrical structures, which in turns
undergo an end-to-end annealing and a radial compaction to obtain the mature long neurofilament
polymer with a diameter of 10 nm [3]. Post-translational modifications like phosphorylation and
O-glycosylation are crucial for neurofilaments aggregation, especially in NfM and NfH [1].
Being highly expressed in large caliber myelinated axons, Nfs are released in the extracellular
space and their levels increase in blood and CSF proportionally to the degree of axonal damage, both in
normal and in pathologic conditions [4]. Physiological ageing has been associated with an increase of
blood and CSF NfL levels, probably due to reduced CSF turnover, slowly progressive structural axonal
damage, and metabolic alterations in Nfs turnover [2]. Moreover, a higher amount of Nfs has been
found in patients affected by various neurological diseases, such as multiple sclerosis, where Nfs have
been found to correlate with disability and disease activity, cerebrovascular diseases, traumatic brain
injury and neurodegenerative disorders, among which Alzheimer’s disease, frontotemporal dementia,
Parkinson’s disease and ALS [2]. In particular, it has been postulated that altered transport of Nfs
down the axon and their subsequent accumulation in the cell body, proximal to the axonal process,
may provoke MNs death in ALS, hypothesizing a role of Nfs in neurodegeneration.
Growing evidence showed that NfL and phosphorylated-NfH (p-NfH) are non-specific markers
of axonal damage and are reported to be increased in CSF and blood of ALS patients, at higher levels
compared to other neurodegenerative disorders or disease mimics [5].
In particular, CSF and serum p-NfH concentrations are significantly increased in ALS in comparison
with controls and ALS mimics, representing a useful diagnostic biomarker, especially in early
symptomatic phases of the disease. NfL elevation in biofluids is the first detectable event accompanying
neurodegeneration in ALS, nevertheless they are less specific for MND, being increased also in other
neurodegenerative disorders. Conversely, both plasma/serum NfL and p-NfH might be used as
prognostic and pharmacodynamic biomarkers, since they are reported to correlate with disease severity
and their blood levels remain stable over time.
In this review, we reported the most relevant studies investigating the role of Nfs in ALS. Describing
the main findings of these works, we highlighted the advantages and the pitfalls of blood and CSF
measurements of p-NfH and NfL, and we discuss their role as potential diagnostic and prognostic
biomarkers in ALS.
Since their reliability and reproducibility, Nfs could represent diagnostic and prognostic biomarkers
useful for precocious identification of patients and their inclusion in clinical trials, assessment of
individual prognosis and response to experimental drugs.
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More than two decades ago, Nfs were discovered at higher levels (5 to 10 folds) in CSF of ALS 
patients, compared to healthy controls (HC) [6]. Given the proximity to the degenerating MNs in 
brain and spinal cord, CSF is expected to contain a greater concentration of Nfs (10 folds higher than 
blood) and could be a more suitable source for the study of these cytoskeletal proteins. 
The improvement of new immunoassays able to detect proteins in biological fluids even if when 
present at low levels, has allowed Nfs measurement also in serum and plasma, providing the 
possibility to conduct longitudinal studies, useful to evaluate biological response to therapies. 
Indeed, first- and second-generation Nfs assays, i.e. immunoblot and enzyme-linked 
immunosorbent assay (ELISA), respectively, were able to detect precisely only high concentrated CSF 
proteins, having a poor sensitivity in detecting Nfs in blood (Figure 1.B). Conversely, third-
generation assays (electrochemiluminescence), and especially fourth-generation assays (single-
molecule array), can measure also ultralow concentrations of blood NfL, allowing to detect even 
subtle longitudinal changes in HC [2]. Further, blood samples are easily accessible and could be 
obtained in a lesser invasive way, providing the possibility to conduct longitudinal studies, useful to 
evaluate biological response to therapies. 
 
Figure 1. A. Overview of neurofilaments structure. Neurofilaments (Nfs) are cylindrical structure of 10 
nm diameter abundantly expressed by large calibre myelinated axons. According to the molecular mass 
of their subunits, Nfs are classified in neurofilament light chain (NfL), neurofilament medium chain 
(NfM), neurofilament heavy chain (NfH) and -internexin (-int). Nfs subunits are formed by a 
conserved -helical rod domain, a variable amino-terminal globular head region and a carboxy-terminal 
tail domain. Each carboxy-terminal tail is variably enriched of glutamic-acid (E), lysine-serine-proline 
(KSP), lysine-glutamic acid-proline (KEP), serine-proline (SP) and lysine-glutamic acid (KE) segments. 
B. Detection methods of Neurofilaments in biological fluids after axonal damage. Axonal injury induces 
Nfs release in extracellular fluids, and subsequently, given its proximity to central nervous system 
(CNS), into cerebrospinal fluid (CSF). First- and second- generation assays (immunoblot and enzyme-
linked immunosorbent assay (ELISA), respectively) are able to measure Nfs levels in CSF, but present 
limited sensitivity for Nfs detection in blood. Third-generation (electrochemiluminescence) and fourth-
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. etection methods of Neurofilaments in biological fluids after axonal damage. Axonal injury
induces Nfs release in extracellular fluids, and subsequently, given its proximity to central nervous
system (CNS), into cerebrospinal fluid (CSF). First- and second- generation assays (immunoblot and
enzyme-linked immunosorbent assay (ELISA), respectively) are able to measure Nfs levels in CSF, but
present limited sensitivity for Nfs detection in blood. Third-generation (electrochemiluminescence)
and fourth-generation assays (single-molecule array) can also detect ultralow concentrations of Nfs in
blood, enabling longitudinal studies in patients and healthy controls (HC).
2. CSF and Blood Neurofilaments as Biomarkers in ALS
The role of Nfs as diagnostic and prognostic biomarkers in MND has been suggested by several
evidence showing that Nfs are found at elevated concentrations in CSF and blood of patients affected
by ALS.
More than two decades ago, Nfs were discovered at higher levels (5 to 10 folds) in CSF of ALS
patients, compared to healthy controls (HC) [6]. Given the proximity to the degenerating MNs in brain
and spinal cord, CSF is expected to contain a greater concentration of Nfs (10 folds higher than blood)
and could be a more suitable source for the study of these cytoskeletal proteins.
Int. J. Mol. Sci. 2019, 20, 4152 4 of 14
The improvement of new immunoassays able to detect proteins in biological fluids even if when
present at low levels, has allowed Nfs measurement also in serum and plasma, providing the possibility
to conduct longitudinal studies, useful to evaluate biological response to therapies.
Indeed, first- and second-generation Nfs assays, i.e. immunoblot and enzyme-linked
immunosorbent assay (ELISA), respectively, were able to detect precisely only high concentrated CSF
proteins, having a poor sensitivity in detecting Nfs in blood (Figure 1B). Conversely, third-generation
assays (electrochemiluminescence), and especially fourth-generation assays (single-molecule array),
can measure also ultralow concentrations of blood NfL, allowing to detect even subtle longitudinal
changes in HC [2]. Further, blood samples are easily accessible and could be obtained in a lesser
invasive way, providing the possibility to conduct longitudinal studies, useful to evaluate biological
response to therapies.
Almost all the studies investigating both CSF and blood compartments on ALS patients have
showed high correlation between CSF and blood Nfs concentrations, with increased Nfs levels than in
blood [7–13].
Several studies have shown that both p-NfH and NfL are found at higher levels in CSF and
blood of ALS patients, not only as compared to controls, but also to disease-mimics (DM), suggesting
their potential utility in differential diagnosis. Furthermore, it has been investigated their role in
distinguishing among different ALS phenotypes.
In a recent metanalysis including 15 studies, levels of CSF and blood Nfs in ALS patients were
compared to HC, ALS mimic and neurological controls with CNS parenchymal involvement [14].
The main findings of this systematic review were that Nfs have actually a role in neurodegeneration in
ALS, in particular, CSF p-NfH and NfL accurately discriminate between ALS and HC, and blood and
CSF NfL could distinguish ALS patients from other neurological diseases. Nevertheless, Nfs are not
specific for this disorder, so they could be likely used as marker of disease progression [14].
3. Phosphorylated Neurofilament Heavy Chain (p-NfH)
NfH undergo post-translational phosphorylation, which is relevant for Nfs transport along the
axons and regulates axon stability and protein-protein interactions.
Compared to NfL, p-NfH are more stable and less susceptible to proteases degradation,
representing a steady and reproducible biomarker in consecutive measurements. Nevertheless,
the presence of immune response against NfH and the hook effect due to p-NfH aggregation in plasma
samples represent an issue in accurate Nfs measurement, since they may accelerate p-NfH clearance or
reduce the binding sites available for antibody binding through ELISA techniques [15].
Different studies have investigated the utility of p-NfH in blood and CSF samples of ALS patients
(Table 1).
Boylan et al. compared p-NfH levels in plasma, serum and CSF in ALS patients, showing a
significant association between higher concentrations and faster disease progression, evaluated as
faster decline in ALS Functioning Rating Scale Revised (ALSFRS-R) [16]. Although to a lesser extent
for CSF, increased serum and plasma p-NfH were associated with shorter survival in ALS patients.
Moreover, they found a mild but significant increase in plasma p-NfH in patients with bulbar versus
spinal onset. These findings support the hypothesis that blood and CSF p-NfH provide a reliable
indicator of disease activity and prognosis in ALS.
Several studies did not find an association between Nfs concentrations and age at onset of ALS,
suggesting a stronger relationship with clinical course than with age of the patients [16]. McCombe
at al. found a significant association between p-NfH peak and age, but no relationship was found
between age and the rise of p-NfH protein [17]. Nevertheless, age could be used as potential covariate
in these studies.
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Table 1. Neurofilament studies in amyotrophic lateral sclerosis. The most relevant studies about neurofilaments (Nfs) in Amyotrophic lateral sclerosis (ALS). For each
study, we reported the first author, the study design, the subtype of Nf analyzed (phosphorylated heavy chain and light chain Nfs, or both), the biological fluid
analyzed (plasma, serum or cerebrospinal fluid), the features of the participants, the main findings of the study, the diagnostic and prognostic relevance of the studies,
and when available, the cut-off level of Nfs able to discriminate patients from controls.
Authors Study Design Neurofilaments TissueAnalysed Participants Main Findings
Diagnostic and/or
Prognostic Relevance Cut-Off
Boylan et al. [2]
Longitudinal;
pilot
(cross-sectional)
p-NfH Plasma, serum,CSF
43 ALS affected patients
(20 patients longitudinally
followed)
Higher p-NfH levels were
associated with faster decline in
ALSFRS-R and shorter survival.
Plasma p-NfH were higher in
patients with bulbar rather than
spinal onset.
p-NfH could be reliable
biomarkers of disease activity
and progression in ALS.
Lu et al. [3]
Cross-sectional;
longitudinal
prospective
p-NfH Plasma
136 patients with ALS (74 of
them longitudinally
followed), 104 healthy and
neurological controls
Fast progressing patients have
higher p-NfH levels than
controls at an early stage and
lower levels at late
disease stage.
Trajectories of plasma p-NfH
reflect the speed of
neurological decline.
Cross-sectional measurement
of plasma p-NfH have a
limited prognostic role
in ALS.
McCombe et al. [4] Longitudinalprospective p-NfH Serum
98 ALS patients and
61 healthy controls
p-NFH increased over time in
early stage of disease, and the
rate of rise inversely correlated
with survival; slow-progressing
patients have lower
p-NfH concentrations.
Initial level of p-NfH is a
marker of disease severity
and changes over time are
marker of
disease progression.
Li et al. [5] Cross-sectional p-NfH Plasma and CSF 51 ALS patients, 12 MSApatients and 30 HC
CSF and plasma p-NfH were
higher in patients than controls
and correlated to each other.
CSF more than plasma p-NfH
correlated with time to
generalization.
p-NfH and TTG could be
indicators of disease survival.
685 pg/ml for p-NfH in plasma
(sensitivity of 80.39% and
specificity of 73.81%), and 589
pg/mL for CSF, with a
sensitivity of 82.35% and a
specificity of 73.81%
De Schaepdryver
et al. [6]
Longitudinal
retrospective p-NfH Serum and CSF
85 ALS patients, 215 DC
and 31 ALS mimics
CSF and serum p-NfH were
increased compared to DC and
ALS mimics, and in ALS
patients they correlated with
disease progression. Serum
p-NfH correlated inversely with
symptom duration. CSF p-NfH
correlated with burden of UMN
and LMN involvement.
The diagnostic potential of
p-NfH measurement in CSF,
more than serum, could be
used as a criterion of
inclusion in clinical trials.
750 pg/mL for CSF p-NfH
discriminating ALS from
mimics, with an elevated
sensitivity and specificity
(92.9% and 96%, respectively).
A cut-off of 81.9 pg/mL in
serum distinguished ALS from
mimics with lower sensitivity
and specificity
(7.8% and 85.2%, respectively).
Int. J. Mol. Sci. 2019, 20, 4152 6 of 14
Table 1. Cont.
Authors Study Design Neurofilaments TissueAnalysed Participants Main Findings
Diagnostic and/or
Prognostic Relevance Cut-Off
Zucchi et al. [7] Cross-sectional p-NfH Serum and CSF
30 patients, among who 14
with UMN-dominant ALS,
7 with PLS and 9 with hSP,
and 9 HC
ALS patients have higher
serum and CSF p-NfH
concentrations compared to HC
and hSP. CSF p-NfH predicted
survival in ALS patients.
Role of CSF p-NfH as a
prognostic biomarker in
diseases presenting with
UMN signs; serum and CSF
p-NfH may have a
diagnostic relevance.
Gendron et al. [8] Cross-sectionaland longitudinal p-NfH CSF
135 C9Orf72 expansion
carriers (asymptomatic,
ALS/ALS-FTS or FTS) and
107 noncarriers (healthy,
ALS/ALS-FTD or FTD); 37
carriers and 17 noncarriers
were followed
longitudinally.
CSF p-NfH discriminated
symptomatic and
asymptomatic carriers and
predict disease severity and
surival in C9-ALS. Higher
p-NfH were associated with
faster disease progression and
shorter survival in C9-ALS.
Use of CSF p-NfH as a
prognostic biomarker in
clinical trials, especially in
patients with hexanucleotide
expansion in C9Orf72 gene.
176 pg/mL in CSF was able to
discriminate with elevated
sensitivity and specificity
(98.8% and 96.4%, respectively)
between symptomatic and
asymptomatic C9Orf72
mutation carriers.
Tortelli et al. [9] Cross-sectional NfL CSF
37 ALS patients, 25 patients
with CIDP and 21 patients
affected by other
neurodegenerative diseases.
CSF NfL were higher in ALS
patients than controls and
showed correlations with
diagnostic delay, the ALSFRS-R
and the progression rate,
probably reflecting the burden
of MNs degeneration.
NfL may be useful marker of
disease activity and
progression in ALS.
1981 pg/mL in CSF
discriminated between ALS
and DC with a sensitivity of
78.4% and specificity of 72.5%.
Lu et al. [10]
Longitudinal,
observational
(two cohorts)
NfL Serum, plasmaand CSF
103 ALS patients and 42 HC
(cohort 1); 64 ALS patients
and 36 HC (cohort 2)
Blood NfL levels at baseline
were higher in fast and
correlate with progression. In
longitudinal measurements
blood NfL were stable
over time.
Blood NfL levels are strong
predictors of survival,
independently from other
clinical variables. Given this
stability over time, NfL may
be reliable pharmacodynamic
biomarkers.
CSF, serum, and plasma NfL
discriminated patients with
ALS from healthy controls with
high sensitivity (97%, 89%, 90%,
respectively) and specificity
(95%, 75%, 71%, respectively).
Menke et al. [11] Cross-sectional NfL Serum and CSF 25 ALS patients and 17 HC
ALS patients have higher NfL
levels and CSF NfL
concentrations correlated with
clinical and imaging UMN
burden, and with rate of
disease progression.
Combined role of
neurochemical and
neuroimaging-based findings
in assessing
neurodegeneration in ALS.
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Table 1. Cont.
Authors Study Design Neurofilaments TissueAnalysed Participants Main Findings
Diagnostic and/or
Prognostic Relevance Cut-Off
Verde et al. [12] Longitudinalprospective NfL Serum
124 ALS patients,
50 patients without
neurodegenerative diseases,
44 patients with disease
mimics and 65 patients with
other
neurodegenerative diseases.
ALS patients presented higher
serum NfL levels respect to
controls, except for CJD. Serum
NfL showed a strong
correlation with progression
rate and survival and they
remained stable over time in
longitudinal analysis.
The authors proposed the use
of serum NfL as a diagnostic
biomarker, useful in at-risk
populations as a screening
test or in patients with recent
onset of symptoms and not
fulfilling El Escorial
diagnostic criteria.
A cut-off level of 62 pg/mL
discriminated between ALS
and disease mimics with a
sensitivity of 85.5% and a
specificity of 77.3%; a cut-off
level of 49 pg/mL discriminated
between ALS and
non-neurodegenerative controls.
Benatar et al. [13] Longitudinalprospective NfL Serum and CSF
84 individual at-risk of
developing ALS, 17 ALS
patients, 34 controls and
10 phenoconverters.
Serum and CSF NfL levels were
higher in ALS patients and in
pre-symptomatic individuals as
far back as 11.6 months before
the onset of ALS, than in
controls and at-risk individuals.
Serum NfL provide a new tool
to quantify pre-symptomatic
disease progression and to
potentially predict the time of
phenoconversion.
Gaiani et al. [14] Longitudinalretrospective NfL CSF
94 ALS patients, 20 FTD
patients, 18 patients with
motor neuropathies and
44 controls.
Higher NfL levels were found
in patients with atypical ALS,
PBP and UMN-dominant, in
comparison with PMA and flail
arm or leg syndrome.
Low NfL levels in patients
with predominant LMN signs
may be prognostic indicator
of milder phenotype
of disease.
Gille et al. [15]
Cross-sectional;
longitudinal (16
ALS patients)
NfL Serum
149 ALS patients (among
whom 15 C9Orf72 mutation
carriers, 15 with ALS-FTD),
19 ALS-mimics.
Serum NfL levels were higher
in ALS as compared to HC
controls and hSP, but not as
compared to GBS and CIDP.
Serum NfL were independent
predictors of survival in ALS
but have low specificity as
diagnostic biomarker.
Steinacker et al.
[16]
Longitudinal
prospective p-NfH and NfL CSF
253 patients with MND
(among whom 242 with
ALS, 11 with PLS and
20 fALS), 85 with MND
mimics, 28 with AD, 26 with
Parkinsonian syndromes,
33 with polyneuropathies
and 30 with facial palsies.
CSF Nfs levels were increased
in MND as compared to MND
mimics and HC. Nfs levels were
associated with MND
progression and
disease duration.
CSF Nfs have a high
relevance in the differential
diagnosis of MNDs.
They found a cut-off level of
2200 pg/mL for NfL, with
sensitivity of 77%, a specificity
of 85% and a PPV of 87%.
For pNfH, a cut-off of 560
pg/mL with 83% sensitivity,
77% specificity and 82% PPV
was obtained.
Weydt et al. [17] Cross-sectional p-NfH and NfL Serum and CSF
12 asymptomatic and 64
symptomatic ALS
mutations carriers and 19
family controls.
CSF p-NfH and serum and CSF
NfL increased at early symptom
onset in symptomatic carriers.
Blood and CSF Nfs are
markers of structural
axonal damage.
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Table 1. Cont.
Authors Study Design Neurofilaments TissueAnalysed Participants Main Findings
Diagnostic and/or
Prognostic Relevance Cut-Off
Poesen et al. [18]
Cross-sectional;
longitudinal
(17 patients)
p-NfH and NfL CSF 220 patients with ALS,316 DC and 50 DM
CSF Nfs were lower in slower
disease progressors and were
correlated to the number of
regions with both UMN and
LMN involvement.
CSF p-NfH are specific for
MND, have a diagnostic
relevance in ALS and can be
used as criteria for early
inclusion of patients in
clinical trials.
pNfH discriminated ALS
patients from DM with a
sensitivity of 90.7%, a specificity
of 88.0% and a likelihood ratio
of 7.6 at a cutoff of 768 pg/mL.
Feneberg et al. [19] Cross-sectionalmulticenter p-NfH and NfL Serum and CSF
Patients with ALS at
<6 months from symptom
onset (54 CSF and 45 serum)
or at >6 months from
symptom onset (135 CSF
and 118 serum), patients
with other neurological
disease (65 CSF and 48
serum), patients with MND
mimics (27 CSF and
21 serum) and patients with
other MND (21 CSF and
16 serum).
CSF and serum NfL and CSF
p-NfH were higher in patients
with ALS than in controls. No
difference was found between
early and later symptomatic
phase, neither between fast and
slow progressors.
Serum and CSF Nfs
effectively discriminate early
ALS patients from
neurological controls.
Rossi et al. [20] Cross-sectional p-NfH and NfL CSF
190 ALS patients (of whom
10 with ALS-FTD) and 130
controls, divided into
patients with
non-inflammatory
neurological diseases and
patients with
acute/subacute
inflammatory neurological
diseases and tumors.
ALS patients have higher CSF
Nfs as compared to patients
with non-inflammatory
neurological diseases. There
was a weak inverse correlation
with diagnostic delay.
The reliability of Nfs as
diagnostic biomarkers is
limited when comparing ALS
patients to diseases with
elevated acute/subacute
neuronal and axonal damage.
AD: Alzheimer’s disease, ALS: amyotrophic lateral sclerosis, ALSFRS-R: ALS Functioning Rating Scale Revised, CIDP: chronic inflammatory demyelinating polyneuropathy, CJD:
Creutzfeldt Jacob disease, CSF: cerebrospinal fluid, DC: disease controls, DM: disease mimics, fALS: familial ALS, FTD: frontotemporal dementia, GBS: Guillan-Barré syndrome, HC:
healthy controls, hSP: hereditary spastic paraplegia, LMN: lower motor neuron, MND: motor neuron disease, MNs: motor neurons, MSA: Multiple System Atrophy, NfL: neurofilament
light chain, Nfs: neurofilaments, PBP: progressive bulbar palsy, PLS: primary lateral sclerosis, PMA: progressive muscular atrophy, p-NfH: phosphorylated neurofilament heavy chain,
PPV: positive predictive value, TTG: time to generalization, UMN: upper motor neuron.
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Lu and colleagues lead a prospective study on 74 ALS affected patients, whose blood samples
have been collected every three months for a period of three years [15]. Although they did not find a
significant difference in plasma p-NfH at baseline between ALS and controls, they observed higher
blood concentrations in patients with shorter disease duration and diagnostic latency, as if plasma
p-NfH levels could reflect the speed of clinical decline and disease progression. Differently from results
obtained in mouse models, in humans plasma concentrations of p-NfH would peak early in patients
with a rapid and aggressive clinical course, decreasing later in the disease, while they would slowly
increase from a low initial level in patients with slower disease progression. These results suggest a
limited role of cross-sectional studies, since they would capture a random snapshot of a biological
indicator, regardless of disease stage and clinical heterogeneity. Therefore, they discuss the prognostic
role of plasma p-NfH and their utility in evaluating treatment response, since changes in plasma p-NfH
levels in a follow-up period do not predict disease progression.
Similar results were obtained from McCombe 2015 et al., who found a significant difference in
blood p-NfH levels at baseline between ALS and HC [17]. Despite a considerable variability, they
showed an increasing trend of plasma p-NfH over time, which was inversely correlated with survival
length: patients with rapidly progressive disease and shorter survival present higher p-NfH levels early,
followed by a fall later in the disease, while lower levels have been observed in slower progressors.
So, higher concentrations and rapid rise in p-NfH levels at the beginning of the disease, may predict
disease severity and prognosis. They did not find a significant relationship between p-NfH levels and
clinical variables like gender, upper motor neuron (UMN)/ lower motor neuron (LMN) predominant
phenotypes, site of onset, use of riluzole and disability measured with ALSFRS-R.
Li and colleagues confirmed the presence of higher p-NfH levels both in plasma and in CSF of
ALS patients in comparison to controls and they identified a cut-off level of 685 pg/ml for p-NfH
in plasma (sensitivity of 80.39% and specificity of 73.81%), and the optimal cut-off value in CSF of
589 pg/mL, with a sensitivity of 82.35% and a specificity of 73.81% [7]. CSF p-NfH levels, more than
blood p-NfH levels, showed an inverse correlation with time to generalization (TTG), and along with
bulbar onset, seem to predict a shorter TTG in ALS patients.
In the retrospective study by De Schaepdryver et al. [8] CSF and matched serum concentrations
of p-NfH were found to correlate well in ALS patients, with higher concentration in CSF, and were
significantly increased in ALS versus disease controls (DC) and DM. To discriminate ALS from mimics,
the authors identified a cut-off value of 750 pg/mL in CSF, with an elevated sensitivity and specificity
(respectively 92.9% and 96%). For serum, the optimal cut-off distinguishing between ALS and DM
was 81.9 pg/mL, with a lower sensitivity and specificity. Even if both serum and CSF p-NfH levels
correlated with disease progression, only the latter was associated with the burden of UMN and
LMN involvement, assessed by clinical and neurophysiological examinations. These findings have
been confirmed by Poesen et al., who found a positive correlation between CSF Nfs and the number
of regions with both UMN and LMN involvement [18]. Hence, the diagnostic potential of p-NfH
measurement in CSF, more than serum, could be used as a criterion of inclusion in clinical trials.
The most relevant finding of the study lead by Zucchi et al. was that CSF and serum p-NfH
can discriminate ALS with predominant UMN signs from other UMN syndromes, like hereditary
spastic paraplegia (hSP) and primary lateral sclerosis (PLS); moreover, CSF p-NfH concentration may
differentiate UMN syndromes from HC and are the most stronger predictors of survivals [9].
Finally, p-NfH in CSF have shown to be a good prognostic biomarker not only in sporadic ALS,
but also in ALS affected patients harboring mutation in the C9Orf72 gene. Gendron and colleagues
identified a cut-off value of 176 pg/mL for p-NfH in CSF, able to discriminate with elevated sensitivity
and specificity (98.8% and 96.4% respectively) between symptomatic and asymptomatic C9Orf72
mutation carriers [19]. Moreover, higher p-NfH levels were associated with faster disease progression
and shorter survival both into this subset of patients and when comparing C9-ALS patients with
asymptomatic carriers and with non-C9Orf72 mutation carriers, likely reflecting an increased neuronal
injury in C9-ALS patients. In longitudinal evaluation, CSF p-NfH levels remained stable over time.
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Similarly, Weydt and colleagues demonstrated that ALS symptomatic carriers presented 10-fold
increased levels of p-NfH in comparison to asymptomatic carriers and HC [13]. According to their
work, Nfs are normal in the asymptomatic phase onset and increased after onset of symptoms in ALS,
representing a marker of neurodegeneration.
In a large prospective study on patients affected by MND, CSF p-NfH were increased as compared
to MND mimics and HC, showing a cut-off level of 560 pg/mL, and were associated with progression
and disease duration [20].
In the work of Poesen et al., CSF p-NfH were shown to have a diagnostic role, since they were
able to discriminate with high sensitivity and specificity (90.7% and 88%, respectively) ALS patients
from DM, with a cut-off of 768 pg/mL [18]. Therefore, being higher in patients with early symptom
onset than in later symptomatic phase, CSF p-NfH can be used as criteria for early inclusion of patients
in clinical trials. While individually were stable over time in group comparison, CSF p-NfH were
found to be significantly higher in patients with intermediate and fast disease progression, showing a
weak prognostic value, but relevant in some subgroups of patients [18].
In the study led by Feneberg et al., CSF p-NfH discriminated patients with early symptoms
from other neurological diseases and MND mimics, confirming their potential utility in precocious
enrollment of patients in clinical trials. Moreover, they were higher in early versus later presenters [21].
4. Light Chain Neurofilament (NfL)
NfL is the lowest molecular weight subunit and the most abundant in axons. Given its high
solubility and precocious diffusion from neural cells into CSF, it is rapidly detectable in biofluids after
axonal degeneration. Accordingly, it presents high sensitivity in diagnosis of MND, being able to early
identify ALS patients from DM. Nevertheless, NfL is an unspecific indicator of axonal damage, so its
potential diagnostic role should be complemented with other neurological assessments [22].
Tortelli and colleagues found elevated CSF NfL levels in ALS respect to DC and identified a cut-off
value of 1981 pg/mL discriminating between the two groups with a sensitivity of 78.4% and specificity
of 72.5% [23]. In ALS patients CSF NfL concentrations showed a significant correlation with diagnostic
delay, the ALSFRS-R and the progression rate, probably reflecting the burden of MNs degeneration.
Lu et al. measured NfL concentrations in serum, plasma and CSF in two cohorts of patients, and
found higher levels in all biofluids in ALS compared to controls, discriminating with high sensitivity
and specificity between ALS patients and HC [10]. Blood NfL levels at baseline were significantly higher
in ALS-fast progressors than in ALS-slow progressors and correlate with progression rate at baseline
(PRB) and progression rate at last visit (PRL). They detected also higher plasma NfL concentrations in
female patients. In longitudinal measurement, there was a steady blood NfL expression over time. As a
matter of fact, blood NfL levels at recruitment predicted survival independently from other clinical
variables, while resulted to be stable over time in longitudinal samples, suggesting a role for NfL as a
prognostic and pharmacodynamic biomarker.
CSF NfL concentrations were compared to measures of Diffusion Tensor (DT) techniques on
brain Magnetic Resonance Imaging (MRI) by Menke and colleagues [11]. Higher CSF NfL levels were
associated with reduced fractional anisotropy (FA) and increased radial diffusivity (RD) in corticospinal
tracts (CSTs) in ALS patients compared to controls, suggesting a combined role of neurochemical and
neuroimaging-based findings in assessing neurodegeneration in ALS.
Verde et al. identified a cut-off level of 62 pg/mL discriminating between ALS and DC, and between
ALS and other neurological diseases, including neurodegenerative diseases, with high sensitivity and
a relatively high specificity [24]. ALS patients presented higher serum NfL levels respect to controls,
except for Creutzfeldt Jacob disease (CJD). In ALS group, serum NfL did not present a statistical
relationship with site of onset, ALSFRS-R at sampling, treatment with riluzole, pathological state
assessed with DTI and presence of C9Orf72 or SOD1 mutations.
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Conversely, NfL showed a strongly significant correlation with progression rate and survival
and, as demonstrated by other studies, they remained stable over time in longitudinal analysis [24].
In consideration of the early rise of NfL levels, followed by a stabilization during the remaining stages
of the disease, the authors proposed the employment of this biological marker in the diagnostic process,
for example in at-risk populations as a screening test or in those patients with recent onset of symptoms
and not fulfilling El Escorial diagnostic criteria.
This is in agreement with the findings of Benatar and colleagues, who found increased serum
and CSF NfL levels not only in ALS patients, but also in pre-symptomatic individuals as far back as
11.6 months before the onset of clinical signs or symptoms of the disease [12]. While longitudinally
measurements of serum NfL were stable both in controls and in ALS patients, in at-risk individuals there
was an increase over time of NfL levels, until at least 6 months after phenoconversion. No difference
was found according to genetic mutations.
Nfs can be considered as markers for the extent of MND, indeed CSF p-NfH and NfL were
reported to be increased with number of regions with both UMN and LMN involvement [18].
Confirming this hypothesis, Gaiani et al. correlated CSF NfL with subtypes of MNs disorders,
identifying higher NfL levels in patients with atypical ALS, progressive bulbar palsy and UMN-dominant,
in comparison with those with progressive muscular atrophy (PMA) and flail arm or leg syndrome [25].
Since MNs composing the CSTs are enriched with Nfs, the high amount of NfL detected in biological
fluids would reflect damage and successive degeneration of pyramidal tracts. As shown by other studies,
NfL levels were found to be constant over time, and patients with a more aggressive disease presented
higher NfL concentrations. In this scenario, the measurement of NfL in patients with predominant
LMN signs, would assume a prognostic value. Moreover, other than ALS, also FTD affected patients
showed higher amount of CSF NfL.
Serum NfL were confirmed to correlate with UMN degeneration by Gille and collegues, and were
reported to be independent predictors of survival in ALS patients [26]. Their levels were higher in
ALS as compared to HC and hSP, probably due to a slow process of neurodegeneration, but not as
compared to acute and chronic demyelinating polyradiculoneuropathy, denoting a low specificity of
NfL for ALS.
In the prospective study of Steinacker et al. CSF NfL showed a high positive predictive value
(PPV) in discriminating MND from other diseases, with a cut-off of 2200 pg/mL; besides they correlated
with disease duration and progression [20].
CSF and serum NfL were found to be increased in patients with early symptoms from
other neurological diseases and MND mimics; nevertheless, no difference in CSF and serum NfL
concentrations have been found between early and later symptomatic phase, neither between fast and
slow progressors [21].
Similarly to p-NfH, CSF and also blood NfL were reported to be massively elevated in symptomatic
mutation carriers, while their levels are low and comparable in controls and asymptomatic carriers [13].
Moreover, Nfs levels were correlated with disease duration but not with severity. These findings
confirmed Nfs as biomarkers of neurodegeneration.
In the study of Rossi and colleagues, CSF pNF-H and NfL levels were found to be increased in
ALS with respect to patients with non-inflammatory neurological diseases and with acute/subacute
inflammatory diseases and tumors, reaching the level of statistical significance only in the first
group [27]. These findings suggest that reliability of Nfs as diagnostic biomarkers is limited when
comparing ALS patients to diseases with elevated acute/subacute neuronal and axonal damage.
No correlation was found between CSF Nfs and site of onset, age at onset and sex, while a weak,
but significant, inverse correlation was found with diagnostic delay [27].
5. Discussion and Future Perspectives
Growing evidence have confirmed the potential utility of p-NfH and NfL as biomarkers in ALS,
both in assessing diagnosis and predicting prognosis, and in monitoring treatment efficacy.
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Considering its high sensitivity and its precocious elevation in biological fluids, NfL are promising
diagnostic biomarkers in neurodegenerative disorders. They are able to discriminate accurately not
only between ALS and HC, but also between ALS and DM; nevertheless, they lack specificity for
MNs damage, since their levels showed relevant increase also in other neurodegenerative disorders.
Therefore, serum and CSF NfL represent useful tools in diagnosis, especially in patients with high
clinical suspicion for MND and when associated with other complementary assessments (clinical,
radiological and electrophysiological biomarkers).
Conversely, the diagnostic utility of p-NfH has been extensively supported by the results of
the above-mentioned studies. In particular, CSF p-NfH showed the higher diagnostic accuracy in
discriminating ALS from both DM and DC in observational and retrospective studies [7,8,18–20].
A common matter in MND diagnosis is that a huge number of patients will not reach the requested
criteria for definitive diagnosis in life or will reach them only in the ending stage of the disease: this
issue could be overcome by adding some biological biomarkers to El Escorial Revised diagnostic
criteria [28], and Nfs dosage in biofluids may represent a valid candidate.
Moreover, it must be taken into considerations the neuroanatomical correlate of Nfs elevation in
biofluids: both p-NfH and NfL correlate with the extent of UMN and LMN involvement, although the
first is primarily associated with LMN damage [18], while the latter better correlates with UMN and
CSTs involvement [11], as demonstrated by DTI-MRI studies.
The vast majority of these works also assessed the prognostic value of blood Nfs in ALS.
Serum and plasma p-NfH concentrations were reported to peak in the early phase of the disease,
especially in patients with shorted diagnostic delay and faster disease progression, probably reflecting
the neurodegenerative process and the trend of neurological decline, and to fall in the later stages of
the disease, when the pool of MNs has been already depleted. The trend of plasma p-NfH identified by
Lu et al. and McCombe et al. [15,17] may reflect the kinetics of neurofilaments clearance from axons,
which in turns depends on the rate of MNs degeneration in brain and spinal cord of ALS affected
patients. Indeed, while during earlier stages of the disease the neurodegenerative process spreads from
a region to another one, involving a great number of axons, and so provoking a rise in concentrations of
Nfs detectable in blood and CSF, in later stages there is a decline in Nfs levels, given the few numbers
of MNs left. In line with this, patients with slower disease progression presented stable p-NfH levels
over time, reproducing a milder rate of neurodegeneration. For this reason, the measurement of p-NfH
in cross-sectional studies has limited utility, since does not take into account disease heterogeneity
in terms of diagnostic delay, disease progression and burden of MNs involvement. On the contrary,
longitudinal studies allow one to follow p-NfH rise over time, enabling to predict disease severity
when tested near symptoms onset, and to estimate disease progression by monitoring the change
of p-NfH levels in the time. Similarly, several studies have shown steady expression of blood NfL
in longitudinal measurements, making blood NfL a promising pharmacodynamic biomarker, useful
to evaluate treatment response. Besides, serum and CSF NfL have also shown a strong prognostic
relevance, since their concentrations at symptom onset predicted disease course. Furthermore, NfL
levels are reported to predict phenoconversion in pre-symptomatic individuals.
Additionally, from a therapeutic perspective, the use of a non-invasive and relatively stable
biomarker may be of paramount importance in potential clinical trials based on neuroprotective drugs.
While in other diseases, like multiple sclerosis, CSF and blood Nfs have been tested in evaluating
the effects of disease-modifying therapies, so far there are no studies investigating the use of Nfs as
indicators of treatment response in ALS. This application would be very important in the current
epoch, as new molecular therapies (i.e. antisense oligonucleotides in SOD1 and C9Orf72 mutated ALS)
are coming to light in the therapeutic scenario of MND.
In conclusion, the diagnostic clinical relevance of Nfs dosage in biofluids, along with the positive
correlation with disease progression and the easy accessibility of this biomarkers, points towards
the standardization and validation of Nfs measurements in clinical activity. Nonetheless, they could
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be employed for improving early diagnosis and monitoring treatment efficacy, thus representing
promising biomarkers in observational and interventional clinical trials.
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